SG11201405621UA - Methods of treating cancer using aurora kinase inhibitors - Google Patents
Methods of treating cancer using aurora kinase inhibitorsInfo
- Publication number
- SG11201405621UA SG11201405621UA SG11201405621UA SG11201405621UA SG11201405621UA SG 11201405621U A SG11201405621U A SG 11201405621UA SG 11201405621U A SG11201405621U A SG 11201405621UA SG 11201405621U A SG11201405621U A SG 11201405621UA SG 11201405621U A SG11201405621U A SG 11201405621UA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- treating cancer
- kinase inhibitors
- aurora kinase
- aurora
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261613258P | 2012-03-20 | 2012-03-20 | |
| PCT/US2013/032962 WO2013142491A1 (en) | 2012-03-20 | 2013-03-19 | Methods of treating cancer using aurora kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201405621UA true SG11201405621UA (en) | 2014-10-30 |
Family
ID=48048255
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201405621UA SG11201405621UA (en) | 2012-03-20 | 2013-03-19 | Methods of treating cancer using aurora kinase inhibitors |
| SG10201607741RA SG10201607741RA (en) | 2012-03-20 | 2013-03-19 | Methods of treating cancer using aurora kinase inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201607741RA SG10201607741RA (en) | 2012-03-20 | 2013-03-19 | Methods of treating cancer using aurora kinase inhibitors |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20130303519A1 (de) |
| EP (1) | EP2827855B1 (de) |
| JP (1) | JP6373252B2 (de) |
| KR (1) | KR102128866B1 (de) |
| CN (1) | CN104271129A (de) |
| AU (1) | AU2013235275B2 (de) |
| CA (1) | CA2868024A1 (de) |
| EA (1) | EA036434B1 (de) |
| ES (1) | ES2746946T3 (de) |
| GE (1) | GEP20186900B (de) |
| HK (1) | HK1206253A1 (de) |
| IL (1) | IL234686B (de) |
| IN (1) | IN2014DN08477A (de) |
| JO (1) | JO3630B1 (de) |
| MA (1) | MA37438A1 (de) |
| MX (1) | MX358411B (de) |
| MY (1) | MY175225A (de) |
| NZ (1) | NZ700744A (de) |
| PH (1) | PH12014502109A1 (de) |
| SG (2) | SG11201405621UA (de) |
| TN (1) | TN2014000387A1 (de) |
| TW (1) | TWI649082B (de) |
| UA (1) | UA117455C2 (de) |
| WO (1) | WO2013142491A1 (de) |
| ZA (1) | ZA201407551B (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
| CN107205933A (zh) * | 2014-12-23 | 2017-09-26 | 米伦纽姆医药公司 | Raf抑制剂与aurora激酶抑制剂的组合 |
| WO2017003845A1 (en) * | 2015-07-02 | 2017-01-05 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to selective inhibitors of aurora a kinase |
| CN114681455A (zh) * | 2018-08-17 | 2022-07-01 | 深圳微芯生物科技股份有限公司 | 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4099012A (en) | 1975-08-28 | 1978-07-04 | Ciba-Geigy Corporation | 2-pyrazolyl-benzophenones |
| IL59316A (en) | 1979-02-07 | 1983-07-31 | Sparamedica Ag | Phenylpyrimidobenzazepine derivatives,their preparation and pharmaceutical compositions containing them |
| US4481142A (en) | 1979-02-07 | 1984-11-06 | Hoffmann-La Roche Inc. | Pyrimido-2-benzazepines |
| US4469633A (en) | 1980-05-16 | 1984-09-04 | Hoffmann-La Roche Inc. | N-oxides of 5-oxo-1-phenyl-2-benzazepines |
| EP0273697A3 (de) | 1986-12-30 | 1989-11-29 | Merck & Co. Inc. | 2-Benzazepine mit 5- und 6-gliedrigen heterozyklischen Ringen |
| US5166151A (en) | 1988-03-25 | 1992-11-24 | Merck & Co., Inc. | 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof |
| US5210082A (en) | 1991-05-16 | 1993-05-11 | Merck & Co., Inc. | 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US5747487A (en) | 1993-07-29 | 1998-05-05 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| KR19990087585A (ko) | 1996-03-08 | 1999-12-27 | 돈 리사 로얄 | 신경학적 활성제로서의 아졸로벤즈아제핀 유도체 |
| AU5330698A (en) | 1996-12-23 | 1998-07-17 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
| GB9713087D0 (en) | 1997-06-20 | 1997-08-27 | Celltech Therapeutics Ltd | Chemical compounds |
| EP1026167B1 (de) | 1997-09-29 | 2003-03-05 | Meiji Seika Kaisha Ltd. | Tricyclische triazolobenzazepinderivate, verfahren zu ihrer herstellung und antiallergische mittel |
| US6277844B1 (en) | 1998-09-14 | 2001-08-21 | Sydney Spector | Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis |
| US6417207B1 (en) | 1999-05-12 | 2002-07-09 | Nitromed, Inc. | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use |
| HUP0302173A2 (hu) | 2000-09-15 | 2003-09-29 | Vertex Pharmaceuticals Incorporated | Protein kináz inhibitorokként alkalmazható pirazolvegyületek |
| ES2265452T3 (es) | 2000-12-21 | 2007-02-16 | Vertex Pharmaceuticals Incorporated | Compuestos de pirazol utiles como inhibidores de la proteina quinasa. |
| SI20848A (sl) | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
| US6686352B2 (en) | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
| DE10135457A1 (de) | 2001-07-20 | 2003-02-06 | Adc Automotive Dist Control | Optische Sensoranordnung |
| JP4364637B2 (ja) | 2001-08-09 | 2009-11-18 | アクテリオン ファーマシューティカルズ リミテッド | 新規なベンゾ縮合へテロ環化合物 |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| CA2554271A1 (en) | 2004-02-10 | 2005-08-25 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent |
| RS50568B8 (sr) | 2004-05-14 | 2019-08-30 | Millennium Pharm Inc | Jedinjenja i postupci za inhibiciju mitotičke progresije inhibiranjem aurora kinaze |
| CA2587427A1 (en) | 2004-11-17 | 2006-05-26 | Miikana Therapeutics, Inc. | Kinase inhibitors |
| WO2006070198A1 (en) | 2004-12-30 | 2006-07-06 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
| MX2008008320A (es) | 2005-12-23 | 2008-09-03 | Smithkline Beecham Corp | Inhibidores de azaindol de aurora cinasas. |
| US8865212B2 (en) | 2006-01-16 | 2014-10-21 | Jubilant Generics Limited | Stable pharmaceutical formulation of an acid labile compound and process for preparing the same |
| AR059838A1 (es) | 2006-03-14 | 2008-04-30 | Ranbaxy Lab Ltd | Formulaciones para dosis estabilizantes de estatina |
| DE102006012301A1 (de) | 2006-03-15 | 2007-09-20 | Cemag-Anlagenbau-Dessau Gmbh | Herstellung von Zementklinker |
| JP2010500352A (ja) | 2006-08-09 | 2010-01-07 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 有糸分裂の進行を阻止するためのピリドベンゾアゼピン化合物および方法 |
| WO2008054808A2 (en) | 2006-10-31 | 2008-05-08 | Achillion Pharmaceuticals, Inc. | Elvucitabine pharmaceutical compositions |
| CL2007003244A1 (es) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| AR065802A1 (es) | 2007-03-22 | 2009-07-01 | Schering Corp | Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas |
| US20090203671A1 (en) | 2007-11-27 | 2009-08-13 | Abbott Laboratories | Method of treating cancer |
| US20110033461A1 (en) * | 2008-03-12 | 2011-02-10 | Vladimir Ratushny | Combination Therapy for the Treatment of Cancer |
| CN105147608B (zh) | 2008-06-26 | 2019-12-10 | 安特里奥公司 | 真皮递送 |
| JO3635B1 (ar) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| JO3434B1 (ar) | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| US8653064B2 (en) | 2010-02-19 | 2014-02-18 | Millennium Pharmaceuticals, Inc. | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate |
| US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
-
2013
- 2013-03-14 US US13/804,570 patent/US20130303519A1/en not_active Abandoned
- 2013-03-18 JO JOP/2013/0075A patent/JO3630B1/ar active
- 2013-03-19 CN CN201380015806.1A patent/CN104271129A/zh active Pending
- 2013-03-19 EP EP13714455.6A patent/EP2827855B1/de active Active
- 2013-03-19 NZ NZ700744A patent/NZ700744A/en not_active IP Right Cessation
- 2013-03-19 AU AU2013235275A patent/AU2013235275B2/en active Active
- 2013-03-19 CA CA2868024A patent/CA2868024A1/en not_active Abandoned
- 2013-03-19 GE GEAP201313599A patent/GEP20186900B/en unknown
- 2013-03-19 IN IN8477DEN2014 patent/IN2014DN08477A/en unknown
- 2013-03-19 SG SG11201405621UA patent/SG11201405621UA/en unknown
- 2013-03-19 JP JP2015501852A patent/JP6373252B2/ja active Active
- 2013-03-19 SG SG10201607741RA patent/SG10201607741RA/en unknown
- 2013-03-19 MA MA37438A patent/MA37438A1/fr unknown
- 2013-03-19 MX MX2014011324A patent/MX358411B/es active IP Right Grant
- 2013-03-19 WO PCT/US2013/032962 patent/WO2013142491A1/en active Application Filing
- 2013-03-19 MY MYPI2014702635A patent/MY175225A/en unknown
- 2013-03-19 EA EA201491727A patent/EA036434B1/ru not_active IP Right Cessation
- 2013-03-19 UA UAA201411324A patent/UA117455C2/uk unknown
- 2013-03-19 ES ES13714455T patent/ES2746946T3/es active Active
- 2013-03-19 KR KR1020147028776A patent/KR102128866B1/ko active IP Right Grant
- 2013-03-20 TW TW102109912A patent/TWI649082B/zh active
-
2014
- 2014-09-15 TN TNP2014000387A patent/TN2014000387A1/fr unknown
- 2014-09-16 IL IL234686A patent/IL234686B/en active IP Right Grant
- 2014-09-22 PH PH12014502109A patent/PH12014502109A1/en unknown
- 2014-10-17 ZA ZA2014/07551A patent/ZA201407551B/en unknown
-
2015
- 2015-07-17 HK HK15106841.1A patent/HK1206253A1/xx unknown
- 2015-09-03 US US14/844,270 patent/US10213436B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288181A (en) | Cancer treatment methods | |
| IL274318A (en) | Cancer treatment with rapamycin target site kinase inhibitors | |
| HK1243919A1 (zh) | 利用tor激酶抑制劑治療癌症 | |
| HK1202247A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
| HK1201750A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
| HK1201753A1 (en) | Treatment of cancer with tor kinase inhibitors tor | |
| HK1206253A1 (en) | Methods of treating cancer using aurora kinase inhibitors | |
| HK1223832A1 (zh) | 用於癌症治療的激酶抑制劑 | |
| EP2897607A4 (de) | Beta-hydrolase-hemmer zur behandlung von krebs | |
| ZA201502294B (en) | Treatment of cancer with tor kinase inhibitors |